garsorasib

Garsorasib is an orally available, small molecule, covalent inhibitor of the KRAS G12C mutant protein. It selectively targets and inhibits the oncogenic KRAS G12C mutation, which is implicated in driving tumor cell growth, proliferation, invasion, and metastasis in various cancers. By binding to the mutant KRAS protein and inhibiting its downstream signaling pathways, garsorasib demonstrates potent antineoplastic activity. The drug was developed by InventisBio and has shown high response rates and durable disease control in patients with previously treated non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations[2][3][7][8].

Brand names

AnFangning

Other names

garsorasibGarsorasib [INN]P491NE9G6ZP-491NE9G6ZP 491NE9G6Z